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Introduction: Adjuvant Aromatase Inhibitors (AIs) predispose breast cancer patients to accelerated bone
loss. Guidelines recommend initial screening and follow up of bone mineral density with dual energy
X-ray absorptiometry (DEXA) scan. In this audit we assessed the rate of adherence to these guidelines
and introduced awareness measures to improve it.
Methods: All post-menopausal women who started upfront adjuvant AIs (letrozole in all patients) be-
tween January 2007 and December 2013 were retrospectively identiﬁed. The standard to be audited was
“These patients should have a baseline DEXA scan requested within the ﬁrst 3 months of starting ad-
juvant AIs therapy”. A 90% or more compliance was accepted as satisfactory. Corrective measures in the
form of educational and awareness sessions followed by re-auditing of the practice over the subsequent
12 months were planned in case of lower compliance rate.
Results: Three hundred and sixty seven eligible patients were identiﬁed. Baseline DEXA scan was per-
formed in 188 (51.2%) patients. As planned, this result triggered the conduction of 4 consecutive edu-
cational sessions over a period of 2 weeks. Re-auditing the practice in the pre-deﬁned subsequent
subjects showed compliance in 47/52 (90.4%) patients.
Conclusion: This study of a sizable cohort conﬁrms previous observations that adherence to skeletal
health guidelines in this patient population is less than adequate. Adherence is improved dramatically by
raising the awareness of relevant physicians.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer (BC) is the most frequently diagnosed cancer and
the leading cause of cancer related death among women world-
wide [1]. The incidence of BC is increasing in many regions of the
world [2].
Surgical resection is the main curative treatment of early BC. In
patients with oestrogen receptor positive (ERþ) tumors, the out-
come can be improved by depriving microscopic disease from
oestrogen. Tamoxifen, a selective ER inhibitor improves recurrence
free survival (RFS) and reduces breast cancer mortality in these
patients [3]. Multiple randomized clinical trials conﬁrmed the
superiority of adjuvant aromatase inhibitors (AIs) when comparedGmbH. This is an open access art
aisal University, Saudi Arabia.with tamoxifen in post-menopausal women [4]. Thus AIs (le-
trozole, anastrazole and exemestane) have become the standard
adjuvant hormonal treatment in post-menopausal women with
ERþ BC. AIs profoundly reduce the levels of circulating oestrogen,
subsequently having deleterious effects on skeletal health. Pro-
longed treatment with AIs increases bone resorption, reduces
bone mineral density (BMD) and increases the risk of fracture [5].
Guidelines and consensus guidance statements highly re-
commend assessment of skeletal health of these patients including
performing a Dual Energy X-ray absorptiometry (DEXA) scan and
subsequent Life style and medicinal intervention guided by T score
results [6–8]. Consequently, oncologists assumed the unusual role
of screening and management of cancer treatment induced bone
loss. Whether these guidelines are implemented in real life daily
practice remains largely an unanswered question. In an attempt to
answer this question, we conducted a large audit to identify if a
baseline DEXA scan was requested at the time of starting adjuvanticle under the CC BY-NC-ND license
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sequent re-auditing of practice.2. Patients and methods
All patients (n¼554) who started any adjuvant hormonal
therapy for newly diagnosed ERþ early BC between January 2007
and December 2013 at King Faisal Specialist Hospital & Research
Centre (Jeddah) were identiﬁed from pharmacy database. Elec-
tronic and paper medical records of these patients were screened.
During the above and the subsequent audit periods, the number of
oncologists treating patients with BC increased from 3 (1 con-
sultant and 2 assistant consultants) to 6 (3 consultants and 3 as-
sistant consultants). All consultants received oncology higher
medical training and certiﬁcation in North America, Canada or
Europe while all assistant consultants were trained in Middle
Eastern countries. Three hundred and sixty seven out of 554 pa-
tients were post-menopausal and started upfront adjuvant AIs
(letrozole in all patients) and were the subject of the primary
audit. The standard to be audited was “These patients should have
a baseline DEXA scan requested within the ﬁrst 3 months of
starting adjuvant AIs therapy”. This information was extracted
from the electronic medical records. Investigators extracted and
analyzed the data over a period of 3 months (July-September
2014). A 90% or more compliance with the standard was accepted
as satisfactory. Corrective measures followed by re-auditing were
planned if lower compliance rate was achieved. Corrective mea-
sures comprised of 4 consecutive educational sessions over a
period of 2 weeks (December 2014) targeting junior and senior
oncologists. The sessions addressed the rational of assessment and
management of skeletal health in these patients and attempted to
raise the awareness to guidelines. These sessions were in the form
power point presentations delivered by the audit lead (the ﬁrst
author of this manuscript). Contents of awareness sessions in-
cluded (a) Effects of AIs on oestrogen synthesis. (b) Bone health
analysis of large adjuvant trials conﬁrming detrimental effect of
AIs on BMD. (c) Local hospital guidelines. (d) International
guidelines and consensus guidance statements including (not
limited to) NICE, ASCO, St Gallen and ESMO guidelines. (e) Clinical
risk factors for fracture. (f) Recommendations of above guidelines:
“A baseline DEXA scan is an integral tool for assessing skeletal
health of patients starting adjuvant AIs for the treatment of ERþ
BC and to offer calcium, vitamin D and bone modifying agents if T
score o2″. (g) Rationale of using bone modifying agents (bi-
sphosphonates and denosumab) in the prevention of AIs induced
bone loss. In particular, oncologists were encouraged to request a
base line DEXA scan for new patients at the time of starting ad-
juvant AIs. Compliance with the standard was planned to be re-
audited for all eligible patients who will receive letrozole during
the subsequent 12 months (January December 2015).Fig. 1. Principles of the clinical audit circle.3. Results
3.1. Compliance with the standard
All patients were under follow up for 46 months from date of
starting adjuvant AIs. Baseline DEXA scan was requested and
performed in 188/367 (51.2%) patients within 3 months of starting
treatment. This compliance rate is considered below the pre-
deﬁned target of 90% and thus corrective measures (as detailed in
methods section) were undertaken. Noncompliance with the audit
standard was seen in 179 (48.8%) patients of whom only 35 pa-
tients had a later (range: 4–49 months) DEXA scan assessment and
there was no evidence of such assessment in the remaining 144patients.
These results were disseminated to all members of the oncol-
ogy team during one of the regular departmental quality meetings.
3.2. Re-audit
Fifty two patients started upfront adjuvant AIs for newly di-
agnosed ERþ early BC between January 2015 and December 2015.
Baseline DEXA scan was requested and performed in 47/52 (90.4%)
patients. These results were disseminated to all oncologists. Re-
levant treating oncologists were notiﬁed of their individual pa-
tients (number¼5 patients) who did not undergo a baseline DEXA
scan during the re-audit period.4. Discussion
Recommendations of international guidelines consistently re-
commend assessment of skeletal health of women with ERþ BC
receiving adjuvant AIs including the performance of a baseline
DEXA scan [7-12]. The United Kingdom (UK) National Institute of
Clinical Excellence (NICE) appraises medical interventions and
publishes quality standards designed to drive improvements
within particular areas of health or care. In addition, NICE con-
siders the cost of these interventions to reassure commissioners
that the services they are purchasing are also cost effective. NICE
guideline clearly recommend performing a baseline DEXA scan to
assess BMD for women with early BC starting adjuvant AIs [6]. In
line with the above, our local guidelines recommend a baseline
DEXA scan for these patients and to offer calcium, vitamin D and
bisphosphonates if T score o2.
Clinical audit is a quality improvement cycle that involves
measurement of the effectiveness of health care against agreed
and proven standards for high quality and taking action to bring
practice in line with these standards so as to improve the quality
of care and health outcomes (Fig. 1).
Based on these principles we designed an audit to identify if a
baseline DEXA scan was requested at the time of starting adjuvant
AIs in post-menopausal women with ERþ BC. The results of our
audit show that about half (48.8%) of eligible patients were not
screened according to guidelines. Consequently, some unscreened
patients will miss the opportunity to receive speciﬁc bone directed
preventative and therapeutic treatment when indicated. To our
knowledge, there are only 3 previous reports in the literature
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levels (38%, 40.7% and 54%) of adherence [13–15].
The reasons for low adherence are not clear. Possible reasons
include: (a) Oncologists may consider bone health a trivial issue in
the context of cancer diagnosis and thus focus on anti-cancer
treatments and follow up to detect recurrence ignoring bone
health. (b) Oncologists may assume that screening for osteoporosis
in these postmenopausal women will be addressed by the general
practitioner or family doctor regardless of the use of AIs.
(c) Oncologists’ historical scope of work centres on the use of anti-
cancer treatments and managing their acute side effects and
therefore long-term bone health issues may seem non-relevant to
the speciality.
We proposed that these 3 possible reasons are likely to arise
from lack of awareness. Therefore, we planned and then con-
ducted educational sessions targeting junior and senior oncolo-
gists to raise the awareness and encourage compliance with the
guidelines (as detailed in Methods section).
Our work is the largest to be reported with 367 patients as-
sessed in the ﬁrst part of the audit compared to 42, 54 and 292
patients in other reports. Methods and results of these report are
summarized in table 1 [13–15]. One of these was only reported in
an abstract form [15]. Only our study and that conducted in the UK
adopted a structured clinical audit design with initial auditing,
introduction of corrective measure and subsequent re-auditing to
complete the audit circle (Fig. 1). The UK audit selected a random
convenience sample of 100 patients with a new diagnosis of BC
diagnosed between April 2012 and April 2013. Only 42 of these
patients were post-menopausal and started adjuvant AIs. Only 38%
(16/42) of these patients received DEXA scans. They disseminated
the results to the breast multidisciplinary team and conducted
relevant educational and awareness activities. This was followed
by re-auditing the practice on monthly basis; January (n¼10),
February (n¼13) and March (n¼11) achieving a collective com-
pliance rate of 32/34 (94.1%) [13]. In contrast, we assessed the
practice in much larger unselected population (n¼367) re-
presenting all eligible patients treated over 7 years. After in-
troduction of corrective measure, we re-audited a larger number
of patients (n¼52) over a longer period of practice of 12 months
(Table 1). Despite these differences, both complete audits followed
the same structured design and concluded similar results which
are: (a) Compliance to guidelines is less than satisfactory.
(b) Compliance is improved by education and raising the aware-
ness to guidelines.
DEXA scan is the gold standard for assessing bone mass in
clinical practice. It measures BMD at the spine and hip. Results canTable 1
Methods and results of reports in the literature auditing the compliance to
guidelines.
Dong H et al. Gibson K et al. Kamboj S et al. Our audit
Reference [13] [14] [15]
Type of report Publication Publication Abstract Publication
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Compliance 94.1% 90.4%be interpreted using the World Health Organization T score. This
information is used to diagnose osteopenia and osteoporosis and
can predict individual's risk of fracture and thus guiding physicians
to advise patients about the use of appropriate treatments [16]. For
these reasons, all guidelines recommend a baseline DEXA scan for
all post-menopausal women starting adjuvant AIs for ERþ early
BC. Such assessment will deﬁne those patients with low BMD and
consequently at risk of developing bone fractures.
Some guidelines (for example, American Society of Clinical
Oncology [ASCO] and National Comprehensive Cancer Network
[NCCN] guidelines) recommend initial assessment and thresholds
for bone-directed therapy based primarily on BMD. Other guide-
lines include clinical risk factors for assessment and treatment
decisions. An international expert panel recommend treatment of
all patients with T score r2.0 and those with at least two of the
following risk factors: T -score o1.5, age 465 years, body mass
index o20 kg m2, family history of hip fracture, personal history
of fragility fracture after 50 years of age, oral corticosteroid
therapy 46 months and cigarette smoking [17]. Additionally, the
panel recommend considering baseline biochemical assessment
including serum calcium, parathyroid hormone and 25-OH-Vita-
min D Levels, and markers of bone turnover [17].
The World Health Organization fracture risk assessment tool
(FRAX) has been developed to evaluate fracture risk in general
population. It is based on individual patient models that integrate
the risks associated with clinical risk factors as well as BMD at the
femoral neck. The FRAX models have been developed from
studying population based cohorts from Europe, North America,
Asia and Australia. The most recent version (FRAX V3.10) was re-
leased in March 2016. Currently available versions have models
suitable for population from 58 countries (not including Saudi
Arabia). In its complete form, the FRAX tool is a computer driven
system in which 12 patient's characteristics are entered. These
characteristics are age, gender, weight, height, previous fracture,
current smoking, use of glucocorticoids, rheumatoid arthritis,
secondary osteoporosis, alcohol consumption of Z3 units/day and
femoral neck BMD.
The use of FRAX is expected to identify those patients at risk of
bone fracture whom otherwise are not identiﬁed solely by BMD
assessment. However, some experts addressed its limitations in
term of accuracy, applicability and practicality. Lewiecki et al.,
explained that sometime FRAX results in values for 10-year
probability of fracture that are counterintuitive and inconsistent
with some of the treatment recommendations. Not all risk factors
are straightforward. Previous fractures are not clearly deﬁned, and
could include fracture sites not related to osteoporosis, such as
ﬁngers and toes. Additionally, some patients with arthritis declare
they have rheumatoid arthritis, although in fact it may be another
form of arthritis. According to the FRAX model, it is possible for
patients with normal T-scores (1.0 or better) to be identiﬁed as
candidates for treatment even though drugs approved for treat-
ment of osteoporosis have not been shown to reduce fracture risk
in patients with T scores better than 1.5. FRAX considers only
femoral neck T score, yet some patients may be at high risk of
fracture with a low lumbar spine T score despite a relatively good
femoral neck T score [18].
Despite the above limitations clinical risk factors/FRAX remain
valuable tools in addition to BMD measurement by DEXA scan in
post-menopausal women starting adjuvant AIs.
Measures to maintain skeletal health and to reverse the process
of bone loss are available. These include changes in life style,
dietary advice, calcium and vitamin D supplements and bone
modifying agents such as bisphosphonates and denosumab [19–
22]. Bisphosphonates, in particular Zoledronic acid has been
shown to have an additional anti-tumour effect [23]. They reduce
the rate of recurrence in the bone and improve breast cancer
J. Zekri, K. Farag / Journal of Bone Oncology 5 (2016) 159–162162survival in post-menopausal women with BC [24,25]. Recently,
denosumab was reported to improve RFS when compared with
placebo in an updated analysis of the ABCSG-18 trial indicating a
probable anti-tumour effect [26]. Detailed discussion of these in-
terventions is beyond the scope of this report.5. Conclusion
This study of the largest reported cohort conﬁrms limited
previous observations that adherence to skeletal health guidelines
in this patient population is less than adequate. Hospitals and
health institutions managing these patients should consider as-
sessing and addressing this issue. Adherence is dramatically im-
proved simply by raising the awareness of relevant physicians.References
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